Estimating the Cost Per Percent Point Reduction in LDL-C for Patients Treated With Pcsk9 Inhibitors in a Large National Health Plan

Value in Health - United Kingdom
doi 10.1016/j.jval.2016.03.125
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Are PCSK9 Inhibitors Cost Effective?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2018English

Disadvantages of Current LDL-cholesterol Lowering and the Role of PCSK9 Inhibitors.

Cardiologia Croatica
Cardiovascular MedicineCardiology
2016English

Effects of Currently Prescribed LDL-C-lowering Drugs on PCSK9 and Implications for the Next Generation of LDL-C-lowering Agents

Lipids in Health and Disease
BiochemistryEndocrinologyClinical BiochemistryMetabolismDiabetes
2011English

A National Plan for Health Service

American Journal of Public Health
1920English

Cost Per Response/Remission in Biologics Available in Italy for the Treatment of TNF-α Inhibitors-Naïve Patients With Ulcerative Colitis

Global and Regional Health Technology Assessment
Health Policy
2019English

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors

INNOVATIONS in pharmacy
2017English

Changes in Serum LDL, PCSK9 and microRNA‑122 in Patients With Chronic HCV Infection Receiving Daclatasvir/Asunaprevir

Biomedical Reports
GeneticsPharmacologyMolecular BiologyBiochemistryNeuroscienceMedicineToxicologyPharmaceutics
2019English

Estimating the Cost of Liver Transplantation in Patients Diagnosed With Chronic Hepatitis C and B in the Uk

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

PCSK9 Inhibitors: A Technology Worth Paying For?

PharmacoEconomics
Health PolicyPublic HealthOccupational HealthPharmacologyEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy